Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.

This drug was developed by MedImmune/AstraZeneca.

References


Oleclumab Wikipedia

Zulassung von Ocrelizumab MSDocblog

Ocrelizumab 06 2018 Heftarchiv AMT

Olaparib_OvaCa.PNG — Onkopedia

AntiCD73(oleclumab biosimilar) mAb 专注肿瘤免疫